Facebook Twitter LinkedIn Google Plus RSS

Celsion gets $15 million in sale of preferred stock

By ,

Biotech company Celsion Corp., in Lawrenceville, announced Friday that institutional investors have agreed to purchase $15 million of the company's securities in a direct offering.

Celsion agreed to sell 15,000 shares of its preferred stock — convertible into a total of approximately 12.1 million shares of common stock — and warrants potentially exercisable for up to approximately 6 million additional shares of its common stock. The estimated net proceeds to Celsion are expected to be approximately $13.8 million.



Also Popular on NJBIZ

Write to the Editorial Department at editorial@njbiz.com

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy


Subscribe to Our Newsletters!
Click Here to Subscribe for Free Now!